Barinthus Biotherapeutics
BRNS
13 hedge funds and large institutions have $48.3M invested in Barinthus Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
367% more capital invested
Capital invested by funds: $10.4M → $48.3M (+$38M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
3.17% less ownership
Funds ownership: 22.53% → 19.35% (-3.2%)
13% less funds holding
Funds holding: 15 → 13 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$119K |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$84.3K |
| 3 |
Renaissance Technologies
New York
|
+$76.7K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$11.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$1.89M |
| 2 |
HF
HRT Financial
New York
|
-$25K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$19K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$16.3K |
| 5 |
Morgan Stanley
New York
|
-$1.53K |
BRNS Hedge Fund Activity: Q4 2025 in Review
13 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q4 2025, worth a combined $48.3M — up 367% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BRNS and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $119K. The largest seller was Alphabet Inc, exiting entirely with an estimated $1.89M sold.
- 13 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q4 2025, down from 15 in Q3 2025.
- Funds reported $48.3M of Barinthus Biotherapeutics stock for Q4 2025, up 367% quarter-over-quarter.
- 3 funds opened new Barinthus Biotherapeutics positions in Q4 2025 and 5 closed out, a net change of -2 holders.
- The largest Barinthus Biotherapeutics buyer in Q4 2025 was Citadel Advisors, an estimated $119K added.
- The largest Barinthus Biotherapeutics seller in Q4 2025 was Alphabet Inc, an estimated $1.89M sold.
Based on aggregated 13F filings for Q4 2025.